Q-omics provides the consensus-scored AWAT1 profile across patient tissues and cancer cell-line models. AWAT1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, AWAT1 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, AWAT1 RNA expression shows 13,071 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, BRCA, and TGCT as cancer lineages where AWAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AWAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AWAT1 survival associations across molecular data types. AWAT1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AWAT1 RNA expression–survival associations across cancer types. High AWAT1 expression shows unfavorable associations in UVM, BLCA, PAAD and COAD, but favorable associations in SCLC and STAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for AWAT1 RNA expression.
This table summarizes AWAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for AWAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AWAT1 shows lower tumor expression in KIRC and COAD and higher tumor expression in BRCA, LUAD, KIRP and THCA. The BRCA box plot shows higher AWAT1 RNA expression in tumor versus normal tissue (log2 FC = +0.259, t-test p = .001).
This table shows molecular features associated with AWAT1 in patient tissues and cancer cell lines. In patient samples, AWAT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, AWAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
